Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure Results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) Trial by O'Connor, Christopher M. et al.
F
C
C
D

M
V
P
t
w
a
I
s
P
t
D
Journal of the American College of Cardiology Vol. 56, No. 9, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PCLINICAL RESEARCH Clinical Trial
Safety and Efficacy of Sertraline for
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Depression and Heart Disease in Chronic Heart Failure) Trial
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Ranga Krishnan, MD,† for the SADHART-CHF Investigators
Durham, Burlington, Chapel Hill, Buies Creek, North Carolina; and Danville, Virginia
Objectives The objective was to test the hypothesis that heart failure (HF) patients treated with sertraline will have lower depres-
sion scores and fewer cardiovascular events compared with placebo.
Background Depression is common among HF patients. It is associated with increased hospitalization and mortality.
Methods The SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial was a randomized,
double-blind, placebo-controlled trial of sertraline 50 to 200 mg/day versus matching placebo for 12 weeks. All par-
ticipants also received nurse-facilitated support. Eligible patients were age 45 years or older with HF (left ventricular
ejection fraction 45%, New York Heart Association functional class II to IV) and clinical depression (Diagnostic and
Statistical Manual of Mental Disorders-Fourth Edition criteria for current major depressive disorder). Those with signifi-
cant cognitive impairment, psychosis, recent alcohol or drug dependence, bipolar or severe personality disorder, ac-
tive suicidal ideation, and current antipsychotic or antidepressant medications were excluded. Primary end points
were change in depression severity (Hamilton Depression Rating Scale total score) and composite cardiovascular sta-
tus at 12 weeks.
Results A total of 469 patients were randomized (n  234 sertraline, n  235 placebo). The mean  SE change from base-
line to 12 weeks in the Hamilton Depression Rating Scale total score was 7.1  0.5 (sertraline) and 6.8  0.5
(placebo) (p  0.001 from baseline, p  0.89 between groups, mean change between groups 0.4; 95% confidence
interval: 1.7 to 0.92). The proportions whose composite cardiovascular score worsened, improved, or was un-
changed were 29.9%, 40.6%, and 29.5%, respectively, in the sertraline group and 31.1%, 43.8%, and 25.1%, respec-
tively, in the placebo group (p  0.78).
Conclusions Sertraline was safe in patients with significant HF. However, treatment with sertraline compared with placebo did not
provide greater reduction in depression or improved cardiovascular status among patients with HF and depression.
(Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure [SADHART-CHF];
NCT00078286) (J Am Coll Cardiol 2010;56:692–9) © 2010 by the American College of Cardiology Foundation
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August 24, 2010:692–9 Sertraline for Depression in HF: The SADHART Trialeart failure (HF) is prevalent in both the U.S. and Europe.
n estimated 5.7 million Americans have HF (1), and there
re at least 15 million patients with HF in the 51 countries
epresented by the European Society of Cardiology (2). HF
s a major cause of death and disability. Despite extensive
herapeutic advances in pharmacologic and device therapies
or HF, morbidity and mortality remain high in this
opulation (3).
Depression is common in HF, with a reported prevalence
f 21.5% (4), and it is one of many factors that contribute to
oor outcome in HF patients (5–8). Depression has been
ndependently associated with a poor quality of life, limited
unctional status, and an increased risk of morbidity and
ortality in this population (4,9–13).
See page 700
Small studies have demonstrated improvements in de-
ressive symptoms and quality of life and decreases in heart
ate and plasma norepinephrine in HF patients treated with
ntidepressants (14,15). Selective serotonin reuptake inhib-
tors (SSRIs) have been shown to inhibit platelet function,
romote endothelial stabilization, and possess anti-
nflammatory properties, although the clinical relevance of
hese properties has yet to be established (16–24). These
harmacologic properties have led to the hypothesis that
SRIs may be associated with cardiovascular benefits be-
ond their antidepressant effects. SSRIs have been shown to
mprove depression scores without adverse cardiovascular
ffects in several studies conducted in patients with acute
yocardial infarction, unstable angina, or stable coronary
rtery disease (25,26). These data suggested that the safety
rofile of sertraline was adequate to permit testing in the
F population. The objective of the SADHART-CHF
Sertraline Against Depression and Heart Disease in
hronic Heart Failure) trial was to evaluate the safety and
fficacy of sertraline in patients with depression and HF.
ethods
he SADHART-CHF trial was a randomized, double-blind
rial of sertraline or placebo in 469 participants with HF and
linical depression. The study was conducted at 3 centers in the
nited States between August 13, 2003, and March 3, 2008.
he protocol was reviewed and approved by the appropriate
nstitutional review board for each center. All participants
rovided written, voluntary informed consent.
ligibility criteria. A complete description of the trial
ethodology was published (27). Briefly, patients 45 years
f age or older with a left ventricular ejection fraction45%
within the previous 6 months), New York Heart Associa-
ion (NYHA) functional class II to IV HF symptoms, and
ajor depressive disorder (as determined by Diagnostic and
tatistical Manual of Mental Disorders-Fourth Edition
riteria) were eligible to participate. HF was confirmed at
he time of presentation by clinical HF specialist cardiolo- wists. The main exclusion criteria
ncluded significant cognitive
mpairment, alcohol or drug de-
endence within the previous
ear, psychoses, bipolar disorder,
evere personality disorder, active
uicidal ideation, life-threatening
omorbidity (estimated 50%
ortality within 1 year), and cur-
ent use of antipsychotic or anti-
epressant medications.
tudy design. The SADHART-CHF trial tested the hy-
othesis that sertraline would improve symptoms of depres-
ion and reduce cardiac events and morbidity/mortality in
F patients with clinical depression to a greater extent than
lacebo. Eligible participants were randomized 1:1 to ser-
raline or matching placebo for the 12-week treatment
eriod. The initial dose was 50 mg/day and was increased in
0-mg/day increments based on the results of the Beck
epression Inventory total score and the clinical opinion of
he examining investigator to a maximum of 200 mg/day.
or patients who were unable to tolerate higher doses, the
ose could be decreased. The minimum dose was 50
g/day. Participants were categorized as completers if they
ompleted 12 weeks of study drug and assessment at the end
f the 12-week intervention, and noncompleters if they
iscontinued study drug before 12 weeks. All participants,
egardless of whether they completed the 12-week treat-
ent period, were included in all analyses as described in
he statistical analysis section.
All participants also received nurse-facilitated support,
esigned to build rapport and trust with the study partici-
ants, ascertain compliance with the study protocol, re-
valuate depression status, monitor suicidal ideation, and
onsult with study physicians on appropriate patient man-
gement. Support was provided by nurses and other study
ersonnel with previous experience or training in clinical
sychiatry, and they conducted interviews with the study
articipants by telephone at 2, 4, 8, and 10 weeks and during
n-clinic or home visits at 6 and 12 weeks. Participants were
lso screened for suicidal ideation. The 17-item Hamilton
epression Rating Scale (HDRS) was completed at base-
ine and at 2-week intervals during the 12-week treatment
hase.
All participants were referred to their primary care
hysician or a psychiatrist for follow-up as indicated after
he initial 12-week period. All participants were followed
ia phone or mail to ascertain clinical events and vital status
very 2 weeks during the 12-week treatment phase and at 6
onths, 1 year, and annually thereafter until the last
articipant completed at least 6 months of follow-up. The
ational death index was used to ascertain vital status of
articipants who could not be reached via phone or mail.
rimary end points. The primary end points of the study
Abbreviations
and Acronyms
HDRS  Hamilton
Depression Rating Scale
HF  heart failure
NYHA  New York Heart
Association
SSRI  selective serotonin
reuptake inhibitorere change across time in the severity of depression
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Sertraline for Depression in HF: The SADHART Trial August 24, 2010:692–9measured by the HDRS total score) and composite cardio-
ascular status (Table 1), both assessed at the end of the
2-week treatment period. Cardiovascular events and sur-
ival during the short-term treatment phase and long-term
ollow-up were also assessed.
djudication of cardiovascular events. All cardiovascular
vents were adjudicated by 3 cardiologists with an HF
ubspecialty who were blinded to treatment assignment. All
ardiovascular events resulting in a procedure or hospital-
zation were adjudicated according to a pre-defined set of
riteria. Each event was reviewed by committee members
eparately and discussed during face-to-face meetings. Dis-
repancies among reviewers were presented and discussed to
chieve consensus for all events.
tatistical analysis. The study was designed to have at least
0% power to detect true between-group differences at the
nd of the 12-week treatment phase. A target enrollment of
00 was proposed during the design stages based on
stimates of: 1) 3-month cardiovascular mortality and read-
ission rates; and 2) 3-month treatment response rate for
epression. Based on published findings, we predicted that
he composite cardiovascular worsening rate would be 35%
n the sertraline group and 50% in the placebo group. Power
alculations indicated that a sample size of 440 (220 per
reatment arm) would yield 80% power to detect a treatment
ifference for the expected rates of the primary cardiovas-
ular end point when applying a 2-sided, continuity-
omposite Cardiovascular ScoreTable 1 Composite Cardiovascular Score
Status Definition
Worsened Any of the following conditions occurred after randomization
All-cause death
Occurrence of1 of the following primary cardiovascular events
Exacerbation of heart failure
Acute myocardial infarction
Atrial/ventricular arrhythmia
Unstable angina
Cardiac syncope
Transient ischemic attack
Stroke/cardiovascular accident
Complications of cardiac medications or cardiac procedures
Permanent discontinuation of double-blind study drug due to
cardiovascular reasons
Permanent discontinuation of double-blind study drug because of
refusal to participate, withdrawal of consent, or other
administrative reasons and at least one of the following occurred
during the post-randomization period:
Primary cardiovascular event on or before discontinuation of
double-blind study drug
Increase in New York Heart Association functional class on or
before discontinuation of double-blind study drug
Death within 7 days after discontinuation of double-blind study drug
Improved The criteria for “worsened” have not been previously met and at least 1
of the following conditions occurred at the last assessment
completed during the post-randomization period
Improvement in New York Heart Association functional class
Heart failure status (as determined by the clinician Chronic Global
Impression–Improvement scale score) is judged to be
moderately to markedly improvedcorrected chi-square test with the level of significance set at
.05. The depression literature suggested a response rate of
0% to 75% for sertraline and a placebo response rate as
igh as 50%. A sample size of 200 (100 per treatment arm)
ould yield at least 80% power to detect a treatment
ifference for expected response rates of 70% and 50% when
sing a 2-sided, continuity-corrected chi-square test with
he level of significance set at 0.05. The primary depression
utcome was the continuous HDRS total scores collected
ver time rather than a dichotomized response score. The
rimary analysis of this measure was a longitudinal analysis
sing a random coefficients regression model. During the
esign stages, sufficient data were not available to estimate the
reatment-by-time effects for HF patients, so the sample size
as based on estimated response rate. It should be noted that
ontinuous measures and longitudinal analysis methods often
rovide greater power than chi-square analyses designed to test
or differences in binary outcomes. Thus, we concluded that a
ample size of 440 would provide 80% power for 2 primary
utcomes. The target enrollment was increased to 500 to adjust
or early termination.
Statistical analyses were performed by statistical person-
el within the Duke University Medical Center, using SAS
ersion 9.1 (SAS Inc., Cary, North Carolina). The primary
nalysis was conducted according to the intention-to-treat
rinciple. Although some participants did not complete 12
eeks of treatment, all participants, regardless of whether
hey completed 12 weeks of treatment, were included in all
nalyses. The complete analytic methods were previously
escribed (27). Briefly, linear random coefficients regression
odels adjusting for the effects of clinical site were used as
longitudinal data analysis method to examine the trajec-
ory of change in HDRS total scores over the acute 12-week
reatment period between the 2 treatment arms. This
ethodology allows all participants with data for at least 1
ime point to be included (n 469) and eliminates the issue
f dealing with missing data. This hierarchical mixed model
ncluded the fixed effects of treatment, the natural log of
ime and natural log of time squared, their interactions with
reatment, and site, as well as the random effects of patient,
atient  time, and square of patient  time. Tests for
ifferences of proportions were used to examine the com-
osite cardiovascular status outcome at the end of acute
reatment. Chi-square tests were used to test for overall
reatment differences, with a Mantel-Haenszel test per-
ormed to examine treatment differences when controlling
or clinical site. The primary analyses were conducted on the
rilevel cardiovascular status outcome.
A per-protocol analysis was also performed. This analysis
ncluded only those participants who completed 12 weeks of
reatment (n 290), and it was conducted on the change in
DRS score over the 12-week period and on the composite
ardiovascular status. The analyses were similar to thoseUnchanged Participant is neither improved nor worsened
onducted on the intention-to-treat sample.
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August 24, 2010:692–9 Sertraline for Depression in HF: The SADHART Trialesults
articipant characteristics. A total of 469 participants
ere enrolled, and their flow through the trial is shown in
igure 1. Baseline characteristics of the study population by
reatment group are shown in Table 2.
tudy drug treatment and discontinuation. A total of 234
articipants were randomized to sertraline. Of these, 138
ere classified as completers. The number of days treated
as 86.1  5.7. The remaining 96 participants (noncom-
leters) received the study drug for 36.7  26.2 days. The
ast dose of sertraline was 65 29 mg/day achieved in those
ompleting 12 weeks of treatment and 63  29 mg/day in
hose who did not. In the placebo group, 152 participants of
he 235 randomized completed the 12-week treatment
eriod and received the study drug for 86.2  5.3 days. The
emaining 83 participants were noncompleters and stopped
aking the study drug after 34.7  26.1 days of treatment.
he mean dose of matching placebo was 92  52 mg/day
chieved in those completing 12 weeks of treatment, and
7  35 mg/day in those who were noncompleters. The
easons for study drug withdrawal are given in Figure 1.
2-week acute-phase end point. HDRS TOTAL SCORE.
he HDRS total score at baseline was 18.3  5.5 in the
ertraline group and 18.3 5.4 in the placebo group. Figure
displays the trajectory of improvement in the HDRS raw
otal scores across the treatment phase. Both groups exhib-
ted a significant reduction in the HDRS total score (time
Figure 1 Participant Flow Through the Trial
Completers were participants who completed 12 weeks of study drug and assessm
discontinued study drug before 12 weeks. Participants were considered noncompl
NFS  nurse-facilitated support. 0.001; time squared p  0.001), but this reduction in
DRS total score was not significantly different between
roups (mean change 0.4; 95% confidence interval: 1.7
o 0.9, treatment-by-time interaction, p  0.89; treatment-
y-time squared interaction p  0.76). The mean  SE
hange from baseline to 12 weeks was7.1 0.5 and6.8
0.5 in the sertraline and placebo groups, respectively.
A total of 8.8% of patients were titrated to 200 mg/day,
.0% to 150 mg/day, 20.6% to 100 mg/day, and 61.7% were
aintained at 50 mg/day. The HDRS scores at baseline
ersus 12 weeks for all the completers among these 4 groups
ere as follows: 21.0 versus 15.6 (200 mg/day); 20.2 versus
.9 (150 mg/day); 18.2 versus 7.6 (100 mg/day); and 17.6
ersus 4.4 (50 mg/day). There was no treatment assignment
y dose interaction (p  0.281).
A longitudinal analysis of HDRS was performed in the
ubgroup of 64 participants with a history of depression and
HDRS score 17 at baseline. The results were similar to
he intention-to-treat analysis. The mean change in HDRS
rom baseline to 12 weeks was 6.2 (p  0.002) in the
ertraline group and 5 (p  0.001) in the placebo group.
here was no difference in change scores between groups
1.3, 95% confidence interval: 3.5 to 6.1; p  0.59).
gain, there was no treatment by dose interaction.
OMPOSITE CARDIOVASCULAR STATUS. In the sertraline
roup, the composite cardiovascular status worsened in
9.9% (70 of 234), improved in 40.6% (95 of 234), and
t the end of the 12-week intervention. Noncompleters were participants who
they did not take the study medication for 14 consecutive days.ent a
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Sertraline for Depression in HF: The SADHART Trial August 24, 2010:692–9emained unchanged in 29.5% (69 of 234). In the placebo
roup, 31.1% (73 of 235) worsened, 43.8% (103 of 235)
mproved, and 25.1% (59 of 235) were unchanged. The propor-
ion of participants classified as worsened, improved, or un-
hanged did not differ significantly between groups (p  0.78).
The 12-week mortality rate was 7% in the overall popu-
ation. No differences were observed between groups in
ndividual components of the composite score, including
ll-cause mortality, cardiovascular death, nonfatal cardiovas-
ular events, HF hospitalization, or combinations of these
aseline CharacteristicsTable 2 Baseline Characteristics
Sertraline
(n  234)
Placebo
(n  235)
Demographic characteristics
Age, mean (SD), yrs 62.9 (10.5) 61.4 (11.1)
Women, n (%) 101 (43.2) 89 (37.9)
Race, n (%)
White 131 (56.0) 136 (57.9)
African American 92 (39.3) 82 (34.9)
Hispanic 0 (0) 2 (0.9)
Heart failure characteristics
New York Heart Association functional class, n (%)
I 0 (0) 0 (0)
II 71 (30.3) 61 (26.0)
III 109 (46.6) 114 (48.5)
IV 54 (23.1) 60 (25.5)
Left ventricular ejection fraction, mean (SD) 31.3 (9.5) 29.5 (10.1)
Ischemic etiology, n (%) 163 (69.7) 163 (69.4)
1 heart failure hospitalization in previous
12 months, n (%)*
134 (57.3) 158 (67.2)
Depression characteristics, mean (SD)
Beck Depression Inventory total score 19.9 (7.2) 18.4 (6.6)
Hamilton Depression Rating Scale total score 18.3 (5.5) 18.3 (5.4)
Depression history, n (%)
Antidepressant use at recruitment 19 (8.1) 15 (6.4)
Major depression 39 (16.7) 25 (20.6)
Cardiovascular history, n (%)
Coronary artery disease 172 (73.5) 159 (67.7)
Myocardial infarction 122 (52.1) 105 (44.7)
Arrhythmia 94 (40.2) 106 (45.1)
Hypertension 212 (90.6) 200 (85.1)
Hyperlipidemia 180 (76.9) 183 (77.9)
Diabetes 126 (53.8) 108 (46.0)
Renal disease 81 (34.6) 87 (37.0)
Percutaneous coronary intervention/stent 83 (35.5) 88 (37.4)
Coronary artery bypass graft surgery 82 (35.0) 78 (33.2)
Implantable cardioverter-defibrillator 45 (19.2) 45 (19.1)
Permanent pacemaker 17 (7.3) 12 (5.1)
Cardiovascular medications, n (%)
Angiotensin-converting enzyme inhibitor 165 (71.4) 165 (70.2)
Angiotensin receptor blocker 22 (9.4) 17 (7.2)
Beta-blocker 202 (86.3) 194 (82.6)
Loop diuretic 144 (61.5) 147 (62.6)
Digoxin 36 (15.4) 44 (18.7)
Statin 168 (71.8) 158 (67.2)
Aspirin 197 (84.2) 194 (82.6)
p  0.03.utcomes (Table 3). VThe total number of days alive during the 12-week acute
hase was similar in both groups: 86.1  15.7 in the
ertraline group and 86.2  15.4 in the placebo group (p 
.61). The distribution of change in NYHA functional class
as also similar among groups. NYHA functional class
orsened in 61 (34.9%) of the sertraline group and 73 (41%)
f the placebo group, and it was unchanged or improved in
14 (65.1%) of the sertraline group and 105 (59%) of the
lacebo group.
A per-protocol analysis (including only those participants
ho completed 12 weeks of treatment) was also performed.
he results for change in HDRS score and composite
ardiovascular score were similar to the findings of the
ntention-to-treat analysis.
OLERABILITY AND SAFETY. A significantly higher propor-
ion of participants in the sertraline arm withdrew from the
Figure 2 Change in HDRS From Baseline to Week 12
Based on raw Hamilton Depression Rating Scale (HDRS) scores. This plot dis-
plays the change in HDRS total scores by week in the study. The primary analy-
sis was conducted based on the natural log of days, with p  0.89.
atal and Nonfatal Events Through 12 WeeksTable 3 Fatal and Nonfatal Events Through 12 Weeks
Event
Sertraline
(n  234)
Placebo
(n  235) p Value
All-cause mortality 18 (7.7) 15 (6.8) 0.58
Cardiovascular death 16 (6.8) 10 (4.3) 0.59
Nonfatal cardiovascular event 47 (20.1) 55 (23.0) 0.39
Acute myocardial infarction 1 (0.4) 0 0.31
Arrhythmia 4 (1.7) 6 (2.6) 0.53
Cardiac syncope 0 1 (0.4) 0.32
Cerebrovascular accident 2 (0.8) 1 (0.4) 0.56
Exacerbation of heart failure 19 (8.1) 30 (12.8) 0.1
Unstable angina 7 (3.0) 5 (2.1) 0.55
Other nonfatal cardiovascular event 14 (6.0) 12 (5.1) 0.68
All-cause mortality or nonfatal
cardiovascular event
65 (29.4) 70 (29.8) 0.63
Heart failure hospitalization or death 37 (15.8) 45 (19.2) 0.34alues are n (%).
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August 24, 2010:692–9 Sertraline for Depression in HF: The SADHART Trialreatment phase because of side effects that were believed to
e study drug related (n 27 of 234; 11.5%) compared with
he placebo group (n 14 of 235; 6.0%) (p 0.03). Nausea
9 of 41 [21.9%] vs. 1 of 41 [2.4%]) and dizziness (4 of 41
9.8%] vs. 2 of 41 [4.9%]) were the most common side
ffects reported with a higher frequency in the sertraline
rm. Serious adverse events were not statistically different
etween the groups (Table 4). Two participants in the
lacebo group developed significant suicidal ideations dur-
ng the acute treatment phase. There were no suicide
ttempts or completed suicides.
ong-term follow-up end points. Participants were fol-
owed for 798  493 days during the long-term follow-up
hase (sertraline group, 788 480 days; placebo group, 808
506 days; p 0.68). All-cause mortality was not different
etween groups. A total of 68 participants (29.1%) in the
ertraline group died compared with 61 (26%) in the
lacebo group. In the Cox model adjusted for site, the
azard ratio for survival was not significantly different
etween the 2 treatment groups (hazard ratio: 1.3, 95%
onfidence interval: 0.66 to 2.58; p  0.45). Nonfatal
ardiovascular events were also similar (Table 5).
iscussion
ll participants in the SADHART-CHF trial demon-
trated improvements in depression scores from baseline.
ultiple reasons may be responsible for the lack of an
bserved additive benefit with sertraline. Placebo effects are
ommon in antidepressant trials. One analysis of 75 anti-
epressant trials found a 30% placebo response rate, defined
s the number of placebo-treated patients who had a 50%
eduction in the HDRS score (28). The placebo response in
his study may have been enhanced by the nursing support
rovided to all participants. An additive benefit of sertraline
n depression scores was not detected. It is possible that the
lose cardiovascular follow-up coupled with the nursing staff
nteractions improved mood disorders to a degree sufficient
o blunt any sertraline effect. It is also possible that the
echanism of depression and mood disorders differs in the
F population, such that their response to traditional
ntidepressant pharmacotherapy is inadequate.
The level of depression in our study may not have been
evere enough to respond to sertraline therapy. A recent
eta-analysis suggests that antidepressants may have min-
mal effect among patients with HDRS scores 23; the
erious Adverse Events byreatment Group at 12 WeeksTable 4 Serious Advers Events byTreatment Group at 12 Weeks
SAE Type
(n  194)
Sertraline
(n  98)
Placebo
(n  96) p Value
Cardiovascular 69 (35.6)* 72 (37.1)* 0.79
Psychiatric† 0 (0)* 2 (1)* 0.16
Noncardiovascular and nonpsychiatric 29 (14.9)* 22 (11.3)* 0.30t
Values are n (%). Percentages are calculated from the total serious adverse events (SAE) (using
 194 as the denominator). †No attempted or completed suicide.aseline HDRS scores in the SADHART-CHF trial were
9.9 and 18.4 in the sertraline and placebo groups, respec-
ively (29).
The mean doses of sertraline achieved in the SADHART-
HF trial may have been insufficient to demonstrate efficacy.
dditionally, the pharmacokinetics of many drugs may be
ltered in the setting of acute decompensation; it is possible
hat higher doses of sertraline may be needed in patients with
recent episode of acute decompensated HF to overcome the
ower absorption that can occur in states of significant volume
verload or reduced cardiac output (and decreased gastrointes-
inal perfusion) states. There are no data evaluating the extent
o which sertraline pharmacokinetics may be altered in acute
F, but this hypothesis may be worth exploring in future
tudies.
Similarly, in the SADHART trial of sertraline in patients
ith acute myocardial infarction or unstable angina, sertra-
ine’s overall effect size on the depression end point was
mall and only significant in the subset of patients with
ecurrent depression (25). These findings may reflect a true
ack of efficacy for sertraline in these populations whose
epression may not be severe enough to benefit from
ertraline or other antidepressants (29). The pathophysiol-
gy of depression in patients with HF or acute myocardial
nfarction/unstable angina patients may have unique char-
cteristics that may be less responsive to antidepressant
herapy.
These data indicate that HF patients with evidence of
epression may benefit from psychosocial supportive care
elivered by clinically experienced personnel. Based on the
ndings of SADHART-CHF, there is no conclusive evi-
ence that antidepressants provide additional benefit to
upportive care in these patients. The use of antidepressant
gents should likely be reserved for patients who do not
espond to supportive care.
The SADHART-CHF study confirmed that patients
ith depression and HF remain at high risk of an adverse
utcome, with a mortality rate of 7% at 12 weeks. This high
vent rate is not an isolated finding; we previously reported
13% mortality rate at 12 weeks in a cohort of HF patients
ith major depression (30). This mortality rate is higher
onfatal Cardiovascular Eventsuring Long-Term Fol ow-upTable 5 N nfatal Cardiova cular EventsDuring Long-Term Follow-up
Event
Sertraline
(n  234)
Placebo
(n  235) p Value
Acute myocardial infarction 10 (4.3) 8 (3.4) 0.63
Arrhythmia 17 (7.3) 20 (8.5) 0.61
Cardiac syncope 6 (2.6) 6 (2.6) 0.99
Cerebrovascular accident 10 (4.3) 4 (1.7) 0.1
Exacerbation of heart failure 64 (27.4) 68 (28.9) 0.7
Unstable angina 23 (9.8) 19 (8.1) 0.51
Other cardiovascular event* 50 (21.4) 59 (25.1) 0.34
alues are n (%). *Includes wound infection, peripheral vascular disease, acute renal failure,
rainage drive line, hypertensive urgency, presyncope, accelerated hypotension, hypotension, deep
enous thrombosis, pre-renal azotemia, graft thrombosis, and nonunstable angina chest pain.han would be expected based on the population’s HF
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ate reported in a similar outpatient HF population with
rimarily NYHA functional class II and III symptoms was
.1% to 8.8% (31). The SADHART-CHF mortality rate is
imilar to the 60- to 90-day post-discharge mortality rate of
.6% reported in patients hospitalized for HF in the
PTIMIZE-HF (Organized Program to Initiate Lifesav-
ng Treatment in Hospitalized Patients With Heart Failure)
egistry (32). This increased short-term mortality rate may
e due to the presence of depression, and it reinforces the
eed to find more effective treatment and management
pproaches for depression in patients with HF.
Sertraline did not influence short- or long-term cardio-
ascular events or survival in this study compared with
lacebo. The proportion of participants whose cardiovascu-
ar status worsened, improved, or was unchanged was
imilar among treatment groups. Fatal and nonfatal cardio-
ascular events were also similar between groups. Thus, the
ncillary properties of SSRIs (16–24) did not translate into
ardiovascular benefit, at least in this short-term study.
A large, ongoing trial will provide further evidence to
uide the management of patients with HF and depression
18). The MOOD-HF (Morbidity, Mortality, and Mood in
epressed Heart Failure patients) study plans to randomize
00 patients to escitalopram 10 to 20 mg/day or placebo for
2 to 24 months. The primary end point is the time to first
eath or hospitalization (18). The results are expected in the
ourth quarter of 2010.
tudy limitations. The SADHART-CHF results should
e evaluated in the context of several limitations. Nurse
upport may have contributed to the placebo response and
mprovement in depression scores, limiting the ability to
etect a difference between groups. The noncompleter rate was
pproximately twice the rate assumed in the sample size
alculations. However, even a larger sample would be unlikely
o affect the results, given the small observed differences
etween groups. Finally, a short-term duration of therapy may
ave been insufficient to fully demonstrate the potential effects
f sertraline on cardiovascular outcomes.
onclusions
epression in patients with HF is associated with substan-
ial mortality. Sertraline did not adversely affect cardiovas-
ular outcomes in this population, and it may be an
ppropriate therapeutic strategy in patients who remain
epressed despite nonpharmacologic interventions and who
therwise have an indication for sertraline. Many patients
ith depression and HF who have coronary heart disease
ay be candidates for depression treatment on the basis of
heir coronary heart disease alone (33). Further research is
eeded to determine the optimal combination of pharma-
ologic and nonpharmacologic treatment of depression in
atients with HF.eprint requests and correspondence: Dr. Christopher M.
’Connor, Duke University Medical Center, DUMC Box 3356,
urham, North Carolina 27710. E-mail: christophe.oconnor@
uke.edu.
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